United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer (PFE) offers $48 per share to buy Array BioPharma and strengthen its cancer portfolio.

Pfizer to Buy Array BioPharma, Broaden Cancer Portfolio

American Electric Power Company

Simon Property Group

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

With summer starting on Friday, we could be in for a hot three months in more ways than one.

5 Dividend Leaders To Buy From Merrill Lynch’s Large Cap Defensive Portfolio

Acquisitions made headlines, with Pfizer buying Array BioPharma.

Pfizer strengthens its position in cancer

The big drugmaker is spending more than $11 billion for the cancer-drug specialist.

Why Pfizer's Acquisition of Array BioPharma Won't Pay Off Anytime Soon

Netflix

Gilead Sciences

Tesla

Gilead Sciences, Pfizer, Tesla, Netflx and Facebook are our top stock trades for Tuesday. Here's a look at the charts.

Five Top Stock Trades for Tuesday June 18

Array BioPharma news for Monday concerning a deal with Pfizer (PFE) that will have the two companies coming together has ARRY stock soaring.

Array BioPharma News: ARRY Stock Skyrockets on Pfizer Deal

Array BioPharma Inc. shares shot up on Monday after the firm announced that it would be acquired by Pfizer Inc. in an all cash transaction.

How Much Is Pfizer Overpaying For Array Bio?

Wall Street was in an optimistic mood on Monday morning.

Stock Market News: Array Get Winning Bids on a Big Deal Day

News on two major mergers in their respective industries are taking headlines, along with a fresh regional economic read.

"Merger Monday" Returns: Pfizer Buying Array

Dow Jones component Pfizer announced Monday an $11.4 billion plan to acquire biotech company Array BioPharma, which is working on cancer treatments.

How An $11.4 Billion Takeover Will Deepen Pfizer's Efforts In Cancer

Pfizer moves to acquire the cancer specialist in a deal valued at $11.4 billion.

Why Array BioPharma Stock Is on Fire Today

S&P Global Ratings placed Pfizer Inc.'s ratings on CreditWatch negative on Monday, after the drug company announced that it is acquiring Array BioPharma Inc.

S&P places Pfizer ratings on CreditWatch negative after $11.4 billion Array deal

Array BioPharma (NASDAQ: ARRY) shares are trading sharply higher after the company announced it will be acquired by Pfizer (NYSE: PFE) for $48 per share in cash for a total value of around $11.4 billion.

Pfizer To Buy Array BioPharma For $48/Share

Shares of Array BioPharma Inc. ARRY, +0.58% rocketed 56% toward a record high in premarket trading Monday, after biopharmaceutical company developing cancer treatments agreed to be acquired by Pfizer Inc.

Array BioPharma's stock rockets after $11.4 billion buyout deal with Pfizer

Pfizer Inc said on Monday it had agreed to acquire Array Biopharma Inc for $10.64 billion, which will grant it access to its cancer drugs.

Pfizer to buy Array for $10.64 billion

AbbVie

Bristol-Myers

Celgene

Johnson & Johnson

Merck

Each of these drugs is forecast to rake in at least $9.5 billion in 2024. Investors looking to profit should pay attention to the pharmaceutical giants that sell them.

5 Biggest Blockbuster Drugs of the Future

Caterpillar

Intel

UnitedHealth Group

Walgreens

It’s been a wild ride in 2019. The seasonal theme of “sell in May and go away” passed and seemingly has turned into “Hold your nose and buy in June.

7 Stocks Not Enjoying the Bull Market and Holding Down the Dow in 2019

Pfizer's (PFE) study on JAK inhibitor Xeljanz XR demonstrates the efficacy of the medicine when used as a monotherapy without methotrexate.

Pfizer's (PFE) Xeljanz Effective As Monotherapy in RA Study

Cisco Systems

Disney

Novartis

According to the GuruFocus All-in-One Screener, the following stocks have outperformed the Standard & Poor's 500 Index over the last 12 months.

6 Large-Cap Stocks Outperforming the Benchmark

Compass Minerals

Kimberly-Clark

Wyndham Destinations Inc

Top Ranked Income Stocks to Buy for June 12th

Top Ranked Income Stocks to Buy for June 12th 2019

Eli Lilly

Teva Pharmaceutical

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials.

Big Pharma Sees a Rising Tide in Short Interest

Roche Holding AG

The large-cap pharma industry is doing well in 2019. Here are three stocks from the space that investors may consider betting on.

Boost Your Portfolio's Health With These 3 Big Drug Stocks

Roku

Sinclair Inc

SeaWorld Entertainment

We have noted that hedge fund performance over the past couple of years, especially by some of the bigger funds, has trailed the overall market performance.

4 Price Momentum Stocks Hedge Funds Love Could Be Big Summer Winners

Apple

Microsoft

It takes a certain kind of courage to short sell blue chips, such as the Dow Jones industrial average components.

News for Pfizer Stock (PFE)